ONTY Key Stats
- Data on Merck KGaA's L-BLP25 - Analyst Blog Zacks May 22
- Data on Merck KGaA's L-BLP25 May 22
- What’s Moving These Biotech Stocks? May 19
- 5 of Last Week's Biggest Losers Fool May 19
- This Week in Biotech Fool May 18
- What’s Moving These Biotech Stocks? Fool May 18
- 3 Horrendous Health-Care Stocks This Week Fool May 18
- Oncothyreon A Speculative Buy May 17
- Wedbush Upgrades Oncothyreon (ONTY) to Outperform Street Insider May 17
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine May 17
ONTY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Oncothyreon is down 45.61% over the last year vs S&P 500 Total Return up 27.77%, Infinity Pharmaceuticals up 94.87%, and Ariad Pharmaceuticals up 16.14%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ONTY
Pro Report PDF for ONTY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ONTY Pro Report PDF
Pro Strategies Featuring ONTY
Did Oncothyreon make it into our Pro Portfolio Strategies?